Saturday, October 3, 2026

EUR/JPY Over 4% Down In The Last 21 Sessions

ViaNews Editorial Team

August 15, 2024

EUR/JPY Over 4% Down In The Last 21 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 4.87% for the last 21 sessions. At 20:09 EST on Wednesday, 14 August, EUR/JPY (EURJPY) is $162.14.

EUR/JPY's yearly highs and lows, it's 9.707% up from its 52-week low and 7.569% down from its 52-week high.

Volatility

EUR/JPY's last week, last month's, and last quarter's current intraday variation average was a positive 0.45%, a negative 0.23%, and a positive 0.38%, respectively.

EUR/JPY's highest amplitude of average volatility was 0.63% (last week), 0.58% (last month), and 0.38% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/JPY's Forex is considered to be oversold (<=20).

Previous days news about EUR/JPY (EURJPY)

  • Eur/jpy clings to gains near daily peak, above mid-161.00s amid weaker JPY. According to FXStreet on Tuesday, 13 August, "Apart from this, geopolitical developments should produce short-term opportunities around the EUR/JPY cross.", "This, along with the lack of any buying around the shared currency, should contribute to capping gains for the EUR/JPY cross."

More news about EUR/JPY (EURJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com